ArticleMolecular carcinogenesis2026
A Combinatorial Model of Serum tsRNAs as a Diagnostic Biomarker for Non-Small Cell Lung Cancer.
Article in Molecular carcinogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Combinatorial Model of Serum tsRNAs as a Diagnostic Biomarker for Non-Small Cell Lung Cancer.Molecular carcinogenesis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
As a promising candidate in liquid biopsy, tRNA-derived small RNAs (tsRNAs) have been implicated as potential diagnostic biomarkers for cancer; however, the diagnostic potential of serum cell-free tsRNAs in non-small cell lung cancer (NSCLC) remains unexplored. This study aimed to develop a combinatorial model based on serum cell-free tsRNA signatures and evaluated its diagnostic performance for NSCLC detection. Through systematic screening from the tsRFun database, we identified 32 NSCLC-related differentially expressed tsRNAs, whose predicted target genes were significantly enriched in the MAPK pathway. Four MAPK pathway-associated tsRNAs were selected for further validation due to their robust discriminatory power in distinguishing NSCLC patients from healthy control. Subsequent validation via quantitative RT-PCR confirmed significantly elevated serum levels of tsRNA-Thr-5-0039, tsRNA-Thr-5-0044, and tsRNA-Cys-5-0011 in NSCLC patients compared to healthy controls. The final combinatorial diagnostic model incorporating these three tsRNAs achieved an AUC of 0.83 (95% CI: 0.70-0.95), with 71.8% accuracy, 52.6% sensitivity, and 90.0% specificity. The three-tsRNA model outperformed individual tsRNAs in diagnostic efficiency. In conclusion, these findings highlight the diagnostic potential of circulating tsRNA signatures as a minimally invasive liquid biopsy approach, offering new perspectives for early diagnosis of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.